Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Sep 23:5:84.
doi: 10.1186/1748-717X-5-84.

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer

Fady B Geara  1 , Ali Shamseddine, Ali Khalil, Mirna Abboud, Maya Charafeddine, Muhieddine Seoud
Affiliations
Clinical Trial

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer

Fady B Geara et al. Radiat Oncol. .

Abstract

Purpose/objective: This is a prospective comparison of weekly cisplatin to weekly paclitaxel as concurrent chemotherapy with standard radiotherapy for locally advanced cervical carcinoma.

Materials/methods: Between May 2000 and May 2004, 31 women with FIGO stage IB2-IVA cervical cancer or with postsurgical pelvic recurrence were enrolled into this phase II study and randomized to receive on a weekly basis either 40 mg/m² Cisplatin (group I; 16 patients) or 50 mg/m² paclitaxel (group II; 15 patients) concurrently with radiotherapy. Median total dose to point A was 74 Gy (range: 66-92 Gy) for group I and 66 Gy (range: 40-98 Gy) for group II. Median follow-up time was 46 months.

Results: Patient and tumor characteristics were similar in both groups. The mean number of chemotherapy cycles was also comparable with 87% and 80% of patients receiving at least 4 doses in groups I and II, respectively. Seven patients (44%) of group I and 8 patients (53%) of group II developed tumor recurrence. The Median Survival time was not reached for Group I and 53 months for group II. The proportion of patients surviving at 2 and 5 years was 78% and 54% for group I and 73% and 43% for group II respectively.

Conclusions: This small prospective study shows that weekly paclitaxel does not provide any clinical advantage over weekly cisplatin for concurrent chemoradiation for advanced carcinoma of the cervix.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier analysis of progression free survival per treatment group.
Figure 2
Figure 2
Kaplan-Meier analysis of Overall survival per treatment group.
See this image and copyright information in PMC

References

    1. Coia L, Won M, Lanciano R. et al. The Patterns of Care study for cancer of the uterine cervix. Results of the Second National Practice Survey. Cancer. 1990;66:2451–2456. doi: 10.1002/1097-0142(19901215)66:12<2451::AID-CNCR2820661202>3.0.CO;2-5. - DOI - PubMed
    1. Einhorn N, Trope C, Ridderheim M. et al. A systematic overview of radiation therapy effects in cervical cancer (cervix uteri) Acta Oncol. 2003;42(5-6):546–56. doi: 10.1080/02841860310014660. - DOI - PubMed
    1. Eifel PJ, Morris M, Wharton JT. et al. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1994;29:9–16. - PubMed
    1. Fyles AW, Pintilie M, Kirkbride P. et al. Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother Oncol. 1995;35(2):107–17. doi: 10.1016/0167-8140(95)01535-O. - DOI - PubMed
    1. Logsdon MD, Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys. 1999;43:763–75. - PubMed

Publication types

MeSH terms